Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients
- 31 December 2007
- journal article
- review article
- Published by Elsevier in The Breast
- Vol. 16 (Suppl 2), 105-113
- https://doi.org/10.1016/j.breast.2007.07.020
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007
- Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancerSteroids, 2006
- Optimising endocrine approaches for the chemoprevention of breast cancer: Beyond the Study of Tamoxifen and Raloxifene (STAR) TrialEuropean Journal Of Cancer, 2006
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI Journal of the National Cancer Institute, 1989
- Short- and long-term estrogen deprivation of T47D human breast cancer cells in cultureEuropean Journal of Cancer and Clinical Oncology, 1989
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- Effects of anti-estrogens on bone in castrated and intact female ratsBreast Cancer Research and Treatment, 1987